CDNA

MKT CAP:$1B

CareDx, Inc

Market Cap

$1B

Healthcare·Medical - Diagnostics & Research·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$20.63+$1.49 (+7.78%)

Apr 22, 2026

Company Details

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloM...

CEO

John Walter Hanna Jr.

IPO Date

Jul 17, 2014

Website

www.caredx.com

Key Metrics TTM

Revenue

$380M

+20.0% YoY

Net Income

-$21M

EPS (Diluted)

-$0.40

Free Cash Flow

$36M

Revenue / Share

$7.43

Gross Margin

67.2%

Operating Margin

-7.5%

Net Margin

-5.6%

FCF Margin

9.6%

P/S

2.9x

P/E

—

Earnings Reports

Q1 2026

Apr 29, 2026

PENDING

FY 2025

Feb 25, 2026

$380M+13.8%EPS -$0.40

Q4 2025

Feb 25, 2026

$108M+25.2%EPS -$0.08

Q3 2025

Nov 4, 2025

$100MEPS $0.03

Q2 2025

Aug 6, 2025

$87M-6.1%EPS -$0.16

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$79M	$52M	-$15M
Q1 22	$79M	$53M	-$19M
Q2 22	$81M	$53M	-$22M
Q3 22	$79M	$51M	-$17M
Q4 22	$82M	$53M	-$19M
Q1 23	$77M	$51M	-$24M
Q2 23	$70M	$44M	-$28M
Q3 23	$67M	$43M	-$29M
Q4 23	$66M	$40M	-$123M
Q1 24	$72M	$46M	-$19M
Q2 24	$92M	$64M	-$7M
Q4 24	$87M	$58M	$75M
Q1 25	$85M	$56M	-$13M
Q2 25	$87M	$58M	-$11M
Q3 25	$100M	$69M	$2M
Q4 25	$108M	$72M	-$6M

Valuation

Quarter	P/S	P/E
Q4 21	8.3x	—
Q1 22	6.5x	—
Q2 22	3.9x	—
Q3 22	2.9x	—
Q4 22	2.0x	—
Q1 23	1.5x	—
Q2 23	1.5x	—
Q3 23	1.2x	—
Q4 23	2.2x	—
Q1 24	2.0x	—
Q2 24	2.7x	—
Q4 24	3.6x	—
Q1 25	2.9x	20.8x
Q2 25	3.1x	19.8x
Q3 25	2.3x	13.3x
Q4 25	2.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	$4M	-$2M
Q1 22	-$21M	-$30M
Q2 22	-$4M	-$11M
Q3 22	-$7M	-$13M
Q4 22	$7M	$4M
Q1 23	$671.0K	-$2M
Q2 23	-$499.0K	-$3M
Q3 23	-$10M	-$13M
Q4 23	-$8M	-$10M
Q1 24	-$15M	-$17M
Q2 24	$19M	$17M
Q4 24	$22M	$20M
Q1 25	-$27M	-$28M
Q2 25	$10M	$9M
Q3 25	$37M	$36M
Q4 25	$21M	$20M

Capital Expenditures

Quarter	CapEx
Q4 21	$6M
Q1 22	$9M
Q2 22	$7M
Q3 22	$6M
Q4 22	$3M
Q1 23	$3M
Q2 23	$2M
Q3 23	$3M
Q4 23	$2M
Q1 24	$1M
Q2 24	$2M
Q4 24	$2M
Q1 25	$2M
Q2 25	$1M
Q3 25	$1M
Q4 25	$2M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	+35.1%	+53.3%
Q1 22	+17.8%	+44.3%
Q2 22	+8.7%	+29.7%
Q3 22	+5.0%	+14.7%
Q4 22	+4.0%	+7.3%
Q1 23	-2.7%	+3.2%
Q2 23	-12.8%	-4.3%
Q3 23	-15.3%	-0.7%
Q4 23	-20.4%	+85.4%
Q1 24	-6.7%	-10.0%
Q2 24	+31.3%	+1.7%
Q4 24	+28.9%	-87.6%
Q1 25	+29.2%	-47.9%
Q2 25	+20.3%	+7.0%
Q3 25	+8.4%	-1.6%
Q4 25	+25.2%	+861.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$9M	12.0%
Q1 22	$11M	13.4%
Q2 22	$13M	15.6%
Q3 22	$11M	14.1%
Q4 22	$12M	14.7%
Q1 23	$14M	17.8%
Q2 23	$13M	18.1%
Q3 23	$13M	18.9%
Q4 23	$10M	15.2%
Q1 24	$13M	18.5%
Q2 24	$16M	17.8%
Q4 24	$26M	30.3%
Q1 25	$9M	10.5%
Q2 25	$9M	10.9%
Q3 25	$8M	8.4%
Q4 25	$8M	7.5%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q4 21	$22M	$25M	$21M
Q1 22	$22M	$27M	$23M
Q2 22	$23M	$25M	$27M
Q3 22	$22M	$24M	$22M
Q4 22	$24M	$25M	$24M
Q1 23	$24M	$28M	$23M
Q2 23	$20M	$29M	$22M
Q3 23	$19M	$34M	$18M
Q4 23	$18M	$27M	$20M
Q1 24	$19M	$27M	$20M
Q2 24	$20M	$31M	$21M
Q4 24	$17M	$41M	$21M
Q1 25	$19M	$23M	$23M
Q2 25	$17M	$28M	$24M
Q3 25	$17M	$28M	$24M
Q4 25	$19M	$29M	$31M

Revenue Segments

Quarter

Revenue by Geography

Quarter	Europe	Rest Of The World	United States
Q3 23	$2M	$2M	$63M
Q1 24	$2M	$1M	$69M
Q2 24	$3M	$1M	$88M
Q4 24	$3M	$1M	$82M
Q1 25	—	$5M	$80M
Q2 25	—	$5M	$82M
Q3 25	—	$5M	$95M
Q4 25	—	—	$103M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$172M	$147M	$319M
Q2 22	$167M	$139M	$306M
Q3 22	$83M	$208M	$291M
Q4 22	$90M	$203M	$293M
Q1 23	$75M	$211M	$286M
Q2 23	$88M	$195M	$283M
Q3 23	$76M	$192M	$268M
Q4 23	$82M	$153M	$235M
Q1 24	$93M	$123M	$216M
Q2 24	$96M	$133M	$229M
Q3 24	$95M	$145M	$241M
Q4 24	$115M	$146M	$261M
Q1 25	$89M	$142M	$231M
Q2 25	$68M	$118M	$186M
Q3 25	$91M	$103M	$194M
Q4 25	$65M	$112M	$177M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	53M	+0.3%	+7.2%
Q1 22	53M	+0.3%	+3.6%
Q2 22	53M	+0.4%	+2.0%
Q3 22	53M	+0.5%	+1.5%
Q4 22	54M	+0.1%	+1.3%
Q1 23	54M	+0.2%	+1.2%
Q2 23	54M	+0.4%	+1.1%
Q3 23	54M	+0.6%	+1.3%
Q4 23	53M	-2.7%	-1.5%
Q1 24	52M	-2.0%	-3.6%
Q2 24	52M	+1.0%	-3.1%
Q4 24	58M	+11.5%	+7.5%
Q1 25	55M	-5.1%	+4.8%
Q2 25	54M	-1.7%	+5.1%
Q3 25	54M	-1.0%	+3.0%
Q4 25	51M	-4.9%	-12.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$122.8K	645
Q1 22	$123.1K	645
Q2 22	$125.0K	645
Q3 22	$123.0K	645
Q4 22	$111.6K	738
Q1 23	$104.7K	738
Q2 23	$95.3K	738
Q3 23	$91.0K	738
Q4 23	$102.0K	643
Q1 24	$112.1K	643
Q2 24	$143.5K	643
Q4 24	$133.2K	650
Q1 25	$130.3K	650
Q2 25	$133.4K	650
Q3 25	$153.9K	650
Q4 25	$141.7K	765

Revenue / Employee